This article first appeared on GuruFocus .
Release Date: July 21, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Embla Medical hf ( FRA:5IQ ) reported strong organic growth of 6% and a total sales increase of 11% in Q2 2026.
-
The prosthetics and neuroorthotics segments experienced double-digit growth, driven by strong execution and new product launches.
-
The company achieved a robust EBITDA margin of 22%, supported by strong performance in key segments and a $3 million U.S. tariff refund.
-
Net profit increased by 39%, attributed to strong operating results and favorable financial expense movements.
-
Embla Medical hf completed a $10 million share buyback program and initiated a new program of similar size, reflecting confidence in its financial position.
Negative Points
-
Sales in the patient care segment declined by 2% in Q2, with underperformance in Europe, particularly in Sweden and France.
-
The company narrowed its full-year organic sales growth guidance from 5%-8% to 5%-7%, indicating potential challenges in meeting higher growth expectations.
-
Despite progress, the patient care business has not yet returned to expected growth levels, with ongoing restructuring and integration challenges.
-
The bracing and supports segment grew only modestly at 1%, facing tough competition and changing market dynamics in EMEA.
-
The anticipated benefits from U.S. Medicare coverage expansion and new product launches are yet to fully materialize, impacting growth projections.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with OSTO:EMBELL.
-
Is FRA:5IQ fairly valued? Test your thesis with our free DCF calculator.
Q: Could you elaborate on the impact of the $3 million tariff refund in Q2 and whether more refunds are expected in H2? Also, how does this affect your margin guidance? A: (CEO) The $3 million tariff refund in the first half is significant, but we might receive an additional $1 million, though it's uncertain. The second half typically sees stronger seasonal performance, providing more operating leverage, especially in patient care. This is the main driver for expected margin improvements, rather than further tariff refunds.
Q: Can you provide insights into the patient care segment's performance, particularly in the Americas and Europe? A: (CEO) We've seen progress in the Americas, with three consecutive quarters of improvement. However, Europe, particularly Sweden and France, has underperformed due to market challenges and integration issues. We're working to normalize growth in line with the OMP industry.
Q: What drove the steep acceleration in new product contributions in the prosthetics business from 2024 to 2025? A: (CEO) The acceleration is due to successful product launches, particularly in bionics like the Navi knee and ICON knee, and innovations in carbon fiber foot products. These strategic R&D investments have resulted in high-quality products and strong demand.
Q: How is the U.S. market performing, and when do you expect to return to market growth? A: (CEO) We anticipate stronger performance in the second half across all business areas, driven by refocused commercial efforts and growth in neuro-orthotics. While we don't expect to lose market share, having a dedicated low-active product would strengthen our range.
Q: Can you discuss the potential for humanoid robotics and partnerships in this segment? A: (CEO) We have significant expertise in applying devices to enhance mobility, which positions us well for potential collaborations in humanoid robotics. While it's an interesting growth area, we're closely monitoring developments without specific commitments yet.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
